Noninvasive Biosensing Device for Respiratory Diseases

This trial aims to test a new device designed to detect and monitor respiratory diseases like COVID-19. The researchers seek to determine if the device can accurately measure breathing, body temperature, heart rate, and blood oxygen levels. Participants will perform a series of simple tasks while their vital signs are monitored. Healthy adults without current signs of infection, such as cough or fever, are ideal candidates for this study. As an unphased trial, this study offers participants the chance to contribute to innovative research that could advance respiratory health monitoring.

You may need to stop taking certain medications if they can cause methemoglobinemia, such as nitrates, sulfonamides, and some anesthetics. If you're on these medications, you might not be eligible to participate.

Research has shown that the PeriFlux 6000 EPOS device, used in this study, is safe and effective. This device is already employed in clinical studies to measure blood flow and oxygen levels noninvasively. It meets high safety standards and incorporates the latest technology.

These devices are easy to tolerate because they remain outside the body. They monitor vital signs like heart rate and breathing externally. The study involves healthy volunteers, focusing on safety and monitoring rather than treatment.

Researchers are excited about this trial because it explores noninvasive biosensing devices for monitoring respiratory diseases, providing a fresh approach compared to traditional diagnostic methods like spirometry or blood tests. These devices, including BIOPAC and Fitbit, offer continuous, real-time tracking of respiratory parameters without the need for invasive procedures. This innovation could lead to more personalized and timely interventions, potentially improving outcomes for patients with respiratory conditions. By utilizing advanced technology like NIRS (Near-Infrared Spectroscopy) and Periflux 6000 EPOS, the trial aims to enhance the precision and convenience of respiratory health monitoring.

Research has shown that noninvasive devices like the PeriFlux 6000 hold promise for checking vital signs and oxygen levels in the body. The PeriFlux 6000 accurately measures blood and oxygen flow, which is crucial for assessing overall health. This capability aids in monitoring breathing problems such as COVID-19. These devices offer a reliable method to track symptoms without invasive procedures. Early findings suggest they effectively help manage breathing issues by providing real-time information.¹⁴⁵⁶⁷